Ignite Creation Date:
2025-12-24 @ 6:41 PM
Ignite Modification Date:
2025-12-27 @ 2:42 PM
Study NCT ID:
NCT02103257
Status:
UNKNOWN
Last Update Posted:
2015-04-29
First Post:
2014-03-31
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
Sponsor:
Betta Pharmaceuticals Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-03
Start Date Type:
None
Primary Completion Date:
2016-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2017-09
Completion Date Type:
ESTIMATED
First Submit Date:
2014-03-31
First Submit QC Date:
None
Study First Post Date:
2014-04-03
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2015-04-27
Last Update Post Date:
2015-04-29
Last Update Post Date Type:
ESTIMATED